

ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS

1. Sakoulas G, Tritos N, Lally MA, Wanke C, Hartzband P.
Hypercalcemia in an AIDS patient treated with growth hormone.
AIDS 11:1353-56, 1997.
2. Harris A, Lally MA, Albrecht M.
Legionella bozemanii pneumonia in three patients with HIV infection.
Clin Infect Dis 27(1):97-9, 1998.
3. Spaulding AC, Lally MA, Rich JD, Dietrich DT.
Hepatitis B & C in the context of HIV disease: implications for incarcerated populations.
AIDS Reader 9(7):481-91, 1999.
4. Farley JL, Adelson Mitty J, Lally MA, Burzynski JN, Tashima K, Rich JD, Cu-Uvin S, Spaulding A, Normandie L, Snead M, Flanigan T.
Comprehensive medical care among HIV-positive incarcerated women: the Rhode Island experience.
J Women's Health Gender-Based Med 9(1):51-6, 2000.
5. Pugatch DL, Levesque BG, Greene S, Strong L, Flanigan T, Lally MA.
HIV testing in the setting of inpatient acute substance abuse treatment.
Am J Drug Alcohol Abuse 27(3):491-99, 2001.
6. Pugatch DL, Levesque BG, Lally MA, Reinert SE, Filippone WJ, Flanigan TP, Brown LK, Combs C.
HIV testing among young adults and older adolescents in the setting of acute substance abuse treatment.
J Acquir Immune Defic Syndr 27(2):135-42, 2001.
7. Pugatch DL, Strong L, Ramratnam M, Levesque BG, Lally MA, Combs C, Patterson D, Brown L.
HIV risk behaviors in young adolescent and young adult substance users undergoing treatment.
J HIV/AIDS Prev Ed Adolesc Child 4(4):43-54, 2001.
8. Rich JD, Hou J, Charuvastra A, Towe C, Lally MA, Spaulding A, Bandy U, Donnelly E, Rompalo A.
Risk factors for syphilis among incarcerated women in Rhode Island.
AIDS Pt Care STDs 15(11):581-85, November 2001.
9. Beckwith CG*, Lally MA.
Missed opportunities for HIV screening: patients diagnosed with HIV in Rhode Island hospital over a two-year period.
RI Med Health 85(11):332, 2002 (*Curt Beckwith, Infectious Diseases Fellow).

10. Lally MA, Alvarez S, MacNevin R, Cenedella C, DiSpigno M, Harwell JI, Pugatch D, Flanigan T.
Acceptability of sexually transmitted infection screening among women in short term substance abuse treatment.
Sex Trans Dis 29(12):752-5, 2002.
11. DeGroot AS, Bishop EA, Khan B, Lally MA, Marcon L, Franco J, Mayer KH, Carpenter CCJ, Martin M.
Engineering immunogenic consensus T helper epitopes for a cross-clade HIV vaccine.
Methods 34(4):476-87, 2004.
12. Flynn, MN, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MH, Gilbert PF, Hudgens MG, Metch BJ, Self SG, Berman PW, Francis DP, Gurwith M, Heyward WL, Jobes DV, Peterson ML, Popovic V, Sinangil FM, Gurwith M, Jobes DV, Peterson ML, Berman PW, Francis DP, Heyward WL, Gilbert PB, Hudgens MG, Self SG, Adamczyk A, Baker RL, Brand D, Brown SJ, Buchbinder S, Buggy BP, Cade J, Caldwell MC, Celum C, Creticos C, Coutinho RA, Lindenburg K, Daly P, DeJesus E, Di-Carlo R, Fenstersheib M, Flynn N, Forthal D, Gripshover B, Gorse GJ, Belshe R, Grossman H, Henry K, Hewitt RG, Hogg R, Jacobson JM, Jemsek J, Judson F, Kahn JO, Keefer MC, Kessler H, Koblin B, Kostman J, Lally MA, Logue K, Marmor M, McKinsey D, Miskin BM, Morales JO, Mulligan MJ, Myers RA, Novak R, Para M, Piliero P, Poblete R, Rhame F, Riddler S, Richter RW, Sampson JH, Sands M, Santiago S, Shikuma C, Somero MS, Thomas E, Thompson M, Tyring SK, Vincelette J, Vrooman PS, Yangco BG, rpg 120 HIV Vaccine Study Group.
Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.
J Infect Dis 191(5):654-665, 2005.
13. Lally MA, MacNevin R, Sergie Z, Hitt R, DiSpigno M, Cenedella C, Stein MD.
A model to provide comprehensive testing for HIV, viral hepatitis, and sexually transmitted infections at a short-term drug treatment center.
AIDS Pt Care STDs 19(5):298-306, 2005.
14. Lally MA, Gaitanis MD, Vallabhaneni S, Reinert S, Mayer K, Zimet G, Rich JD.
Willingness to receive an HIV vaccine among incarcerated persons.
Prev Med 43(5):402-405, 2006.
15. Tedeschi SK*, Bonney LE*, Manalo R, Mayer KH, Shepardson S, Rich JD, Lally MA.
Vaccination in juvenile correctional facilities: state practices, hepatitis B, and the impact on anticipated sexually transmitted infection vaccines.
Pub Health Rep 122(1):44-8, 2007. (*Sara Tedeschi, Pre-Med Research Assistant; Loida Bonney, T32 Research Fellow).
16. Beckwith CG, Atunah-Jay S, Cohen J, Macalino G, Poshkus M, Rich JD, Flanigan TP, Lally MA.
Feasibility and acceptability of rapid HIV testing in jail.

AIDS Pt Care STDs 21(1):41-7, 2007.

17. Beckwith CG, Cohen J, Shannon C, Raz L, Rich JD, Lally MA.
HIV testing experiences among male and female inmates in Rhode Island.
AIDS Reader 17(9):459-64, 2007.
18. Lally MA, Montstream-Quas S, Tanaka S, Tedeschi S, Morrow K.
A qualitative study among injection drug using women in Rhode Island: attitudes toward testing, treatment, and vaccination for hepatitis and HIV.
AIDS Pt Care STDs 22(1):53-64, 2008.
19. Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J, Santiago S, Marmor M, Lally MA, Novak RM, Brown SJ, Kulkarni P, Dubey SA, Kierstead LS, Casimiro DR, Mogg R, DiNubile MJ, Shiver JW, Leavitt RY, Robertson MN, Mehrotra DV, Quirk E, for the Merck V520-016 Study Group.
Safety and immunogenicity of a replication-incompetent adenovirus type-5 HIV-1 Clade B gag/pol/nef vaccine in healthy adults.
Clin Infect Dis 46(11):1769-81, 2008.
20. Quirk EK, Mogg R, Brown DD, Lally MA, Mehrotra DV, DiNubile MJ, Robertson MN.
HIV seroconversion without infection after receipt of adenovirus-vectored HIV-1 vaccines.
Clin Infect Dis (accepted for publication), 2008.

OTHER PEER-REVIEWED PUBLICATIONS

1. Mylonakis E, Paliou M, Lally MA, Flanigan TP, Rich, JD.
Laboratory Testing for Infection with the Human Immunodeficiency Virus: Established and Novel Approaches.
Am J Med 109(7):568-76, 2000 (review).
2. Beckwith CG*, Lally MA, Flanigan TP.
Routine HIV Testing among Inpatients.
Arch Intern Med 162(19):2252-3, 2002 (letter to the editor). (*Curt Beckwith, Infectious Diseases Fellow).
3. Rich JD, Ching CG, Lally MA, Gaitanis MM, Schwartzapfel B, Charuvastra A, Beckwith CG*, Flanigan, TP.
A review of the case for hepatitis B vaccination of high-risk adults.
Am J Med 114(4):316-8, 2003.
4. Simmons E, Lally MA, Flanigan TP.
Routine, not risk-based, human immunodeficiency virus testing is the way to go.
J Infect Dis 187(6):1024, 2003 (letter to the editor).

5. Beckwith CG*, Simmons E, **Lally MA**, Flanigan TP.
Testing for HIV infection: should it be routine?
Res Staff Phys 50(4):9-15, 2004 (featured article). (*Curt Beckwith, Infectious Diseases Fellow).
6. Bonney LE*, **Lally, MA**, Williams D, Stein MD, Flanigan TP.
Where to begin human papillomavirus vaccination.
Lancet Infect Dis 6(7):389-390, 2006 (letter to the editor). (*Loida Bonney, T32 Research Fellow).
7. **Lally MA**, Lemei KD, Bonney LE, Zimet GD.
HPV vaccination: an opportune time for HIV testing. (Letter to the editor)
J Adolesc Health 40:384-5, 2007.
8. **Lally MA**, Lemei KD, Mayer K.
HIV vaccine update: recent developments and current trials.
Med Health RI 90(10):318-20, 2007 (review).

OTHER NON-PEER-REVIEWED PUBLICATIONS

1. Pugatch DL, **Lally MA**, Combs C, Rich JD, D'Angelo L, Brown LK.
Intranasal heroin use and HIV prevention: opportunities to intervene in strategies to improve the replicability, sustainability, and durability of HIV prevention interventions for drug users.
NIDA/CAMCODA Working Meeting, Chevy Chase, MD, May 6-7, 2002.
National Institute on Drug Abuse, U.S. Dept. of Health and Human Services, National Institutes of Health (Meeting Proceedings) July, 2003.

MULTICENTER TRIAL PUBLICATIONS

1. Harro CD, Judson FN, Gorse GJ, Mayer KH, Kostman JR, Brown ST, Koblin B, Marmor M, Bartholow BD, Popovic V, for the **VAX004 Study Group**.
Recruitment and baseline epidemiologic profile of participants in the first phase 3 HIV vaccine efficacy trial.
J Acquir Immune Defic Syndr 37(3):1385-92, 2004. (*Michelle A. Lally, Principal Investigator for VAX004, Brown/Miriam HIV Vaccine Clinical Trial Site*).
2. Montefiori DC, Metch B, McElrath MJ, Self S, Weinhold KJ, Corey L, for the **HIV Vaccine Trials Network**.
Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines.
J Infect Dis 190(11):1962-9, 2004. (*Michelle A. Lally, Principal Investigator for HVTN 063 and HVTN 039, Brown/Miriam HIV Vaccine Clinical Trial Site, HVTN*).

3. Goepfert PA, Horton H, McElrath MJ, Gurunathan S, Ferrari G, Tomaras GD, Montefiori DC, Allen M, Chiu YL, Spearman P, Fuchs JD, Koblin BA, Blattner WA, Frey S, Keefer MC, Baden LR, Corey L, and the **NIAID HIV Vaccine Trials Network**.
High-dose recombinant canarypox vaccine expressing HIV-1 protein, in seronegative human subjects.
J Infect Dis 192(7):1249-59, 2005. (**Michelle A. Lally**, Principal Investigator for HVTN 039, Brown/Miriam HIV Vaccine Clinical Trial Site, HVTN).
4. Bartholow BN, Buchbinder S, Celum C, Goli V, Koblin B, Para M, Marmor M, Novak RM, Mayer K, Creticos C, Orozco-Cronin P, Popovic V, and Mastro TD for the **VISION/VAX004 Study Team**.
HIV sexual risk behavior over 36 months of follow-up in the world's first HIV vaccine efficacy trial.
J Acquir Immune Defic Syndr 39(1):90-101, 2005. (**Michelle A. Lally**, Principal Investigator for VAX004, Brown/Miriam HIV Vaccine Clinical Trial Site).
5. Colfax G, Buchbinder S, Vamshidar G, Celum C, McKirnan D, Neidig J, Koblin B, Gurwith M, Bartholow B.
Motivations for participating in an HIV vaccine efficacy trial.
J Acquir Immune Defic Syndr 39(3):359-64, 2005. (**Michelle A. Lally**, Principal Investigator for VAX004, Brown/Miriam HIV Vaccine Clinical Trial Site).
6. Djomand G, Katzman J, Tommaso D, Hudgens MG, Counts GW, Koblin BA, Sullivan PS and the **HIV Vaccine Trials Network**.
Enrollment of racial/ethnic minorities in NIAID-funded networks of HIV vaccine trials in the United States, 1988 to 2002.
Public Health Rep 120(5):543-8, 2005. (**Michelle A. Lally**, Principal Investigator for all HVTN Studies Enrolled at Brown/Miriam HIV Vaccine Clinical Trial Site, 2001-2002).
7. Goepfert PA, Tomaras GD, Horton H, Montefiori D, Ferrari G, Deers M, Voss G, Koutsoukos M, Pedneault L, Vandepaperliere P, McElrath MJ, Spearman P, Fuchs JD, Koblin BA, Blattner WA, Frey S, Baden LR, Harro C, Evans T, and the **NIAID HIV Vaccine Trials Network (HVTN 041)**.
Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.
Vaccine 25(3):510-8, 2006. (**Michelle A. Lally**, Principal Investigator for HVTN 041, Brown/Miriam HIV Vaccine Clinical Trial Site, HVTN).
8. Russell ND, Graham BS, Keefer MC, McElrath MJ, Self SG, Weinhold KJ, Montefiori DC, Ferrari G, Horton H, Tomaras GD, Gurunathan S, Baglyos L, Frey SE, Mulligan MJ, Harro CD, Buchbinder SP, Baden LR, Blattner WA, Koblin BA, Corey L, and the **National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network**.
Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial.

J Acquir Immune Defic Syndr 44(2):203-12, 2007. (**Michelle A. Lally**, Principal Investigator for HVTN 203, Brown/Miriam HIV Vaccine Clinical Trial Site, HVTN).

9. Fuchs J, Durham M, McLellan-Lemal E, Vittinghoff E, Colfax G, Gurwith M, Buchbinder S.
Negative social impacts among volunteers in an HIV vaccine efficacy trial.
J Acquir Immune Defic Syndr 46(3):362-68, 2007. (**Michelle A. Lally**, Principal Investigator for VAX004, Brown/Miriam HIV Vaccine Clinical Trial Site).
10. Jaspen HB, Cunningham CK, Tucker TJP, Wright PF, Self SG, Sheets RL, Rogers AS, Bekker LG, Wilson CM, Duerr A, Wasserheit JN, and the **HIV Vaccine Adolescent Trials Working Group.**
Inclusion of adolescents in preventive HIV vaccine trials: public health policy and research design at a crossroads.
J Acquir Immune Defic Syndr 47(1):86-92, 2008. (**Michelle A. Lally**, Member of HIV Vaccine Adolescent Trials Working Group).
11. Russell GJ, Baden LR, Wecker M, Newman MJ, Ferrari G, Weinhold KJ, Livingston BD, Villafana TL, Li H, Noonan E, Russell ND, and the **HIV Vaccine Trials Network.**
Safety and immunogenicity of cytotoxic T-lymphocyte polyepitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults.
Vaccine 26(2):215-23, 2008. (**Michelle A. Lally**, Principal Investigator for HVTN 048, Brown/Miriam HIV Vaccine Clinical Trial Site, HVTN).

PUBLICATIONS SUBMITTED

1. Harro CD, Mehrotra DV, O'Neill LD, **Lally MA**, Dubey SA, Kierstead LS, Casimiro DR, Kulkarni P, DiNubile MJ, Shiver JW, Leavitt RY, Robertson MN, for the **Merck V520-007/012 Study Groups.** Safety and immunogenicity of adenovirus-vectored HIV-1 clade B consensus gag vaccines in healthy adults. (submitted), 2008.